MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

Search

Bristol-Myers Squibb Co.

Suletud

SektorTervishoid

59.47 -2.51

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

59.23

Max

60.97

Põhinäitajad

By Trading Economics

Sissetulek

-1.1B

76M

Müük

442M

12B

P/E

Sektori keskmine

14.05

73.239

Aktsiakasum

1.67

Dividenditootlus

4.06

Kasumimarginaal

0.616

Töötajad

34,100

EBITDA

-1.9B

2.6B

Soovitused

By TipRanks

Soovitused

Neutraalne

12 kuu keskmine prognoos

+2.32% upside

Dividendid

By Dow Jones

Dividenditootlus

Sektori keskmine

4.06%

3.06%

Järgmine tulemuste avaldamine

24. apr 2025

Järgmine dividendimakse kuupäev

1. mai 2025

Järgmine aktsia dividendi kuupäev (ex-date)

4. apr 2025

Turustatistika

By TradingEconomics

Turukapital

-744M

120B

Eelmine avamishind

61.98

Eelmine sulgemishind

59.47

Uudiste sentiment

By Acuity

40%

60%

138 / 386 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Bearish Evidence

Bristol-Myers Squibb Co. Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

11. märts 2025, 10:13 UTC

Suurimad hinnamuutused turgudel
Omandamised, ülevõtmised, äriostud

2seventy Bio Shares Soar Premarket on Deal to be Acquired by Bristol Myers

11. märts 2025, 10:13 UTC

Suurimad hinnamuutused turgudel
Omandamised, ülevõtmised, äriostud

2seventy Bio Shares Soar Premarket on Deal to be Acquired by Bristol Myers

6. veebr 2025, 12:13 UTC

Tulu

Bristol Myers Squibb's 4Q Beats Forecasts; Generics Dent 2025 Outlook

14. märts 2025, 09:30 UTC

Peamised uudised

Big Pharma Walked Away From Mental Health. Why Some Are Coming Back. -- Heard on the Street -- WSJ

11. märts 2025, 02:26 UTC

Omandamised, ülevõtmised, äriostud

Abecma Is an Immunotherapy Indicated for Treatment of Relapsed or Refractory Multiple Myeloma >TSVT

11. märts 2025, 02:26 UTC

Omandamised, ülevõtmised, äriostud

Stockholders Owning About 5.3% of 2seventy Bio Shares Have Agreed to Tender All Their Shares >TSVT

11. märts 2025, 02:26 UTC

Omandamised, ülevõtmised, äriostud

2seventy Bio CEO: Rationale for Deal Clear, in Line With Focus on Unlocking Value of Abecma >TSVT

11. märts 2025, 02:23 UTC

Omandamised, ülevõtmised, äriostud

2seventy Bio Stock Will No Longer Trade on Nasdaq After Closing of Deal, Expected in 2Q >TSVT

11. märts 2025, 02:22 UTC

Omandamised, ülevõtmised, äriostud

2seventy Bio's Board Unanimously Recommends Stockholders Tender Shares in Offer >TSVT

11. märts 2025, 02:21 UTC

Omandamised, ülevõtmised, äriostud

Bristol Myers Deal Represents 88% Premium to 2seventy Closing Price of $2.66 on March 7 >TSVT

11. märts 2025, 02:21 UTC

Omandamised, ülevõtmised, äriostud

Bristol Myers to Acquire 2seventy Bio Shares at $5.00 Each in All-Cash Deal for Equity Value of About $286M >TSVT

11. märts 2025, 02:19 UTC

Omandamised, ülevõtmised, äriostud

2seventy Bio Enters Into Definitive Agreement to Be Acquired by Bristol Myers Squibb

28. veebr 2025, 12:00 UTC

Peamised uudised

Drug Stocks Are the New Safe Bet in a Shaky Market -- Heard on the Street -- WSJ

6. veebr 2025, 15:35 UTC

Tulu

Bristol Myers Wallops Fourth-Quarter Views, But Shares Slide On 2025 Outlook -- IBD

6. veebr 2025, 13:56 UTC

Tulu

Bristol Myers Wallops Fourth-Quarter Earnings Views. But Shares Plummet 5%. -- IBD

6. veebr 2025, 13:25 UTC

Peamised uudised
Tulu

Bristol Myers Earnings Are a 'Tale of 2 Trends' as Guidance Falls Short. The Stock Is Falling -- Barrons.com

6. veebr 2025, 12:00 UTC

Tulu

Bristol Myers Earnings Are 'a Tale of 2 Trends' as Guidance Falls Short -- Barrons.com

6. veebr 2025, 11:59 UTC

Tulu

Bristol-Myers Squibb 4Q Gross Margin 61.0% >BMY

6. veebr 2025, 11:59 UTC

Tulu

Bristol-Myers Squibb 4Q Rev $12.3B >BMY

6. veebr 2025, 11:59 UTC

Tulu

Bristol-Myers Squibb 4Q Net $72M >BMY

6. veebr 2025, 11:59 UTC

Tulu

Bristol-Myers Squibb 4Q EPS 4c >BMY

6. veebr 2025, 11:59 UTC

Tulu

Bristol-Myers Squibb 4Q Adj EPS $1.67 >BMY

6. veebr 2025, 11:59 UTC

Tulu

Bristol Myers Squibb: Expanding Existing Strategic Productivity Initiative to Include About $2B in Additional Annualized Cost Savings by the End of 2027 >BMY

6. veebr 2025, 11:59 UTC

Tulu

Bristol Myers Squibb 4Q International Revenue Rose 5% to $3.7B >BMY

6. veebr 2025, 11:59 UTC

Tulu

Bristol Myers Squibb 4Q U.S. Revenue Rose 9% to $8.6B >BMY

6. veebr 2025, 11:59 UTC

Tulu

Bristol Myers Squibb 4Q Legacy Portfolio Revenue $5.98B, Down 4% >BMY

6. veebr 2025, 11:59 UTC

Tulu

Bristol Myers Squibb: 4Q Growth Portfolio Revenue Primarily Due to Higher Demand for Reblozyl, Breyanzi, Camzyos, Yervoy and Opdualag >BMY

6. veebr 2025, 11:59 UTC

Tulu

Bristol Myers Squibb 4Q Rev $12.34B >BMY

6. veebr 2025, 11:59 UTC

Tulu

Bristol Myers Squibb: 4Q Legacy Portfolio Revenue Lower Vs Yr-Ago Primarily Due to Impact of Generics on Sprycel, Revlimid, Abraxane and Pomalyst, Partially Offset by Higher Demand for Eliquis >BMY

6. veebr 2025, 11:59 UTC

Tulu

Bristol Myers Squibb: 2025 Rev Outlook Reflects Near-Term Impact of Generics Across Revlimid, Pomalyst, Sprycel and Abraxane >BMY

Võrdlus sarnastega

Hinnamuutus

Bristol-Myers Squibb Co. Prognoos

Hinnasiht

By TipRanks

2.32% tõus

12 kuu keskmine prognoos

Keskmine 60.93 USD  2.32%

Kõrge 70 USD

Madal 37 USD

Põhineb 16 Wall Streeti analüütiku instrumendi Bristol-Myers Squibb Co. 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Neutraalne

16 ratings

5

Osta

10

Hoia

1

Müü

Tehniline skoor

By Trading Central

59.18 / 59.9Toetus ja vastupanu

Lühikene perspektiiv

Bearish Evidence

Keskpikk perspektiiv

Bullish Evidence

Pikk perspektiiv

Weak Bearish Evidence

Sentiment

By Acuity

138 / 386 Pingereas Tervishoid

Uudiste sentiment

Languse märgid

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Alla keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Bristol-Myers Squibb Co.

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Onureg for the treatment of AML; Inrebic for the treatment of myelofibrosis; Camzyos for the treatment of symptomatic obstructive HCM to enhance functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane to treat breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey.